Innovation Dynamics today announced exciting new data revealing that over 450 drugs are in development by Australian biotechnology and pharmaceutical companies, with a significant number of compounds in advanced clinical trials. These findings have been released in Innovation Dynamics’ Australia New Zealand (ANZ) Drug Pipeline database, which is the leading, most comprehensive regional Drug Pipeline database commercially available.
“Our new data indicates that the biotechnology industry is clearly maturing, with more companies moving forward into phase III trials and looking toward reaching market” said Dr Lyndal Thorburn, Managing Director of Innovation Dynamics.
Dr Thorburn said ‘the Australian drug development pipeline is looking very strong, with a total of 182 compounds in human clinical trials (phase I to III), and a significant proportion (60%) of these in phases II and III.”
Our analysis has revealed an 8% increase in the number of drugs in development since this time last year. The most significant increase was in oncology, already the largest therapeutic area, rising 29% in twelve months. Neurology (and Analgaesia) also showed a significant increase, rising 16% in the last twelve months. The Drug Pipeline database provides information on development by both publicly listed and private companies, the latter being not readily available from public sources. It details over 450 drugs grouped into ten therapeutic indications, covering early stage research / discovery to pivotal phase III clinical trials.
Information from the database is used by Australian and international pharmaceutical companies, government agencies, venture capital investors and service providers.
For more information contact: Managing Director, Innovation Dynamics: Dr Lyndal Thorburn (02) 6239 9500 Sales inquiries: Ms Erin Brady (02) 9209 4241
About Innovation Dynamics Pty Ltd Innovation Dynamics is a corporate advisory firm with offices in Sydney, Melbourne, Canberra, Brisbane and Perth. The Company helps other organisations and companies to grow and to commercialise their products, raise capital and can assist in finding merger and acquisition partners. The firm holds an Australian Financial Services Licence No. 295107 and prepares expert reports, valuations and fair and reasonable assessments for companies listing on the Australian Securities Exchange. The Company also markets several software packages for technologybased companies.
Innovation Dynamics also publishes the BioIndustry Review - Australia & New Zealand, which is recognised as an authoritative source of information on the Australian and New Zealand biosciences industry. The 2008 Review issue will be launched in Sydney on 21 February 2008. www.innovationdynamics.com.au
